Pedmarqsi (sodium thiosulfate solution for infusion) has become the first treatment to be made available within NHS Scotland for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients up to 18 years of age with localised, non-metastatic, solid tumours. The decision follows that of the National Institute for Health and Care Excellence […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!